Pfizer Inc. is facing a growing wave of litigation over its contraceptive injection, Depo-Provera, following the recent approval by the FDA of a warning about the risk of brain tumors associated with the drug. More than 2,100 lawsuits have been filed in the United States, a fivefold increase since May, by women who developed intracranial meningioma, a type of brain tumor, after using Depo-Provera. The lawsuits allege that Pfizer failed to adequately warn patients and doctors about this risk, despite evidence from peer-reviewed studies. The cases are being coordinated in a Multidistrict Litigation proceeding, with the first trial date set for December 2026. A law firm representing plaintiffs argues that Pfizer did not properly investigate safety signals or update warning labels, resulting in serious harm to patients. Additionally, at least one law firm is investigating potential shareholder legal action against Pfizer's Board of Directors for alleged breaches of fiduciary duties related to the marketing and sale of Depo-Provera.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107690108) on January 07, 2026, and is solely responsible for the information contained therein.
Comments